drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Patient-derived T cells genetically engineered to express a chimeric antigen receptor targeting CD19 on B-lineage cells; HLA-independent antigen binding triggers CD3ΞΆ/co-stimulatory signaling to activate T cells, leading to proliferation, cytokine secretion, and perforin/granzyme-mediated killing of malignant B cells (with expected on-target B-cell aplasia).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor; HLA-independent binding to CD19 triggers CD3zeta and co-stimulatory signaling, leading to T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated lysis of CD19-positive malignant B cells, with expected on-target B-cell aplasia.
drug_name
CD19-directed autologous CAR-T cells
nct_id_drug_ref
NCT06647329